We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byFay Perkins
Modified over 4 years ago
CHARM Program: 3 Component trials comparing candesartan with placebo
CHARM Program: Baseline characteristics
CHARM Program: Baseline medications
CHARM-Overall: CV death and non-CV death
CHARM Program: Reduction in mortality and morbidity
CHARM Program: Reduction in CHF hospitalization
CHARM-Preserved: Hospital admissions for CHF
CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis
CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)
CHARM-Added: Effect of combined ACE inhibitor/ -blocker/AT1-receptor blocker
CHARM-Overall: Drug discontinuations for adverse events
CHARM: Clinical implications
CHARM-Overall: Reduction in new-onset diabetes
CHARM: Impact of treatment
HF with preserved LV systolic function in the elderly: Impact on survival
CHARM-Preserved: CV death or CHF hospitalization
CHARM-Preserved: Primary and secondary outcomes
CHARM-Preserved: Clinical implications
VALIANT: Concomitant medications
VALIANT: Treatments show similar effect on outcome
VALIANT: Clinical implications
VALIANT: Effect of treatment on mortality—Subgroup analysis
RESOLVD: Comparative impact of ACE inhibitor, ARB, and -blocker alone or combined on LVEF
Differences in dosing among ARB trials
Survival studies of -blockade in HF
-Blockers improve survival in diabetic patients with HF: A meta-analysis
MERIT-HF: -Blockade improves survival in CHF
MERIT-HF: -Blockade improves survival in post-MI patients with HF
MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)
SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction
MERIT-HF: Effect of -blockade on heart rate
MERIT-HF: -Blockade decreases mortality and hospitalization independent of resting heart rate
CHRISTMAS: Trial profile
CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation
COMET: Trial profile
COMET: All-cause mortality
COMET: Heart rate at each visit
COMET: Blood pressure
-Blocker HF trials: Mortality results
Mortality rates in perspective CIBIS-II, MERIT-HF, COMET
Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences
COMET: Clinical implications
Comparison of -blocker effects in major HF trials
Not all -blockers are the same
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
Purpose To determine whether metoprolol controlled/extended release
Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
analysis from the SHIFT study
A randomised, double-blind, placebo-controlled phase III study
SOLVD (Studies of Left Ventricular Dysfunction)
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
© 2019 SlidePlayer.com Inc. All rights reserved.